Prostaglandins and the management of congenital heart disease
- PMID: 6890758
Item in Clipboard
Prostaglandins and the management of congenital heart disease
Am Fam Physician.
1982 Dec.
Abstract
Either continued patency or closure of the ductus arteriosus is needed to improve survival of infants with certain kinds of congenital heart disease. In many of these infants, the use of prostaglandin (PGE1) or a prostaglandin synthetase inhibitor (indomethacin) permits clinical stabilization in preparation for surgery or makes surgery unnecessary. Although these forms of therapy carry some risk, the risk does not outweigh that of the untreated congenital defects.
Similar articles
-
The ductus arteriosus: why and how to manipulate its patency.J Fla Med Assoc. 1983 Sep;70(9):788-93. J Fla Med Assoc. 1983. PMID: 6355376 Review. No abstract available.
-
Cardiovascular therapy in the newborn.Clin Invest Med. 1985;8(4):360-7. Clin Invest Med. 1985. PMID: 3907921 Review.
-
Pharmacological manipulation of the ductus arteriosus.Arch Dis Child. 1986 Sep;61(9):827-9. doi: 10.1136/adc.61.9.827. Arch Dis Child. 1986. PMID: 3767410 Free PMC article. No abstract available.
-
Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.Adv Prostaglandin Thromboxane Res. 1980;7:913-6. Adv Prostaglandin Thromboxane Res. 1980. PMID: 6768235 No abstract available.
-
Comments on the pharmacologic manipulation of the ductus arteriosus in newborns.Adv Prostaglandin Thromboxane Res. 1978;4:383-5. Adv Prostaglandin Thromboxane Res. 1978. PMID: 645513 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Medical